

## **Financial Information**

## Revenue (Millions of yen)




Sales from new flagship products OPDIVO Intravenous Infusion, FORXIGA Tablets, and ORENCIA Subcutaneous Injection rose and royalty revenue increased so revenue rose by 16.8% year-on-year to 361.4 billion yen.

#### **Profit for the year** (attributable to owners of the parent company)(Millions of yen)




Current net income rose by 6.8% year-on-year, to 80.5 billion yen due to a decrease in corporate income tax in addition to to higher pre-tax net income.

# Basic earnings per share (yen)



## Operating profit (Millions of yen)



Although Cost of sales, Research and development costs, Selling, general and administrative expenses all increased, and also Other expenses increased significantly due to a one-time expense, revenue also increased significantly, resulting in a 4.9% increase year-on-year to 103.2 billion yen.

### R&D costs / Ratio to revenue (Millions of yen / %)



Aggressive R&D investment is necessary for sustainable growth, and in recent years we have invested 20-25% of sales revenue in R&D.


### Dividend per share / Consolidated payout ratio (yen / %)



ONO considers the distribution of profits to shareholders as a vital management policy. ONO will prioritize stable dividend distribution, appropriately distributing its profits in line with its business performance.

#### **Non-Financial Information**


## Number of employees (people)



We recruit not only new graduates but also midcareer workers and others with a variety of different backgrounds to strengthen our corporate infrastructure.

Expansion of human capital, p.47


# Number of mid-career hire employees (people)



We focus on hiring people with the skills, knowledge, and experience necessary for our company.

Expansion of human capital, p.47


## Comprehensive medical examination rate (%)



We take an approach to actively maintaining and improving the health of employees and their families. We have a support system in place for disease prevention, early detection, and treatment. Eligibility: Insured employees aged 35 and over and their dependent spouses

Expansion of human capital, p.47


### Number of female employees / Ratio of female to male workforce / Retention rate



As part of initiatives for promoting diversity, we have made efforts to promote women's participation and advancement in the workplace.

Expansion of human capital, p.47

## CO<sub>2</sub> emissions (thousand tons-CO<sub>2</sub>)



In accordance with our environmental policy, we have set numerical targets and are working to achieve them.

▶ Protection of environment, p.65

# No. of participants in ONO's annual walking campaign (people)



Each year, ONO hosts a walking campaign at the company. The event is growing in popularity each year, and encourages ONO employees and their family members to take up walking.

Expansion of human capital, p.47

ONO CORPORATE REPORT 2022 ONO CORPORATE REPORT 2022